Drug Design & Development Lab
A five-stage medicinal chemistry and formulation design pipeline: Disease Intelligence, Database Sweep, Client Context, Interrogation, Design Output. The Lab generates scaffold rationale, risk tables, and first-experiment plans — hypotheses a medicinal chemist or formulation scientist can evaluate at the bench.
Short answer. The Drug Design Lab produces design hypotheses, not predictions. Predict & Optimize routines are gated behind real uploaded bench data. Without your DoE screens, PK, stability, or assay results, the system will not produce a prediction from a scaffold description alone.
What it produces
- Disease intelligence: pathophysiology, patient population, unmet need, regulatory endpoints, treatment landscape, competitive pipeline.
- Client context: target, indication, route, goal, hard constraints, trial history (failed / positive), prior notes.
- Interrogation stage: three sharp, data-driven questions a senior medicinal chemist would ask before committing to a scaffold.
- Design Output (7 sections): Design Hypothesis, Molecular Scaffold, Data Signals That Shaped This Design, Known Failures Avoided, Top 3 Risks and Mitigations, First Experiment, Confidence Assessment.
- Follow-up conversation: after Stage E, a chat panel with full report context for delta analysis (scaffold variants, route switches, TPP drafting, IND-enabling study scope).
What it does NOT do
- Predictions without data. Predict & Optimize routines require real uploaded bench data — DoE screens, PK, stability, assay outputs. No prediction is generated from scaffold descriptions alone.
- Assay execution. It does not run screens, synthesize molecules, or perform bench chemistry.
- IND submission. It produces design content that feeds Module 2 and Module 3 authoring, not the submission itself.
Regulatory and scientific grounding
Design hypotheses cite real precedent trials with DOI or PMID where available and flag when no verified source exists (no fabricated PMIDs or NCT identifiers). Risk tables reference ICH Q9(R1) FMEA methodology. Confidence assessments use explicit numeric scales with 95% CI framing where relevant. All citations default to USD for any commercial or cost reference.
Common follow-up prompts
- "Suggest 3 alternative molecular scaffolds for this target."
- "What if we switched to a transdermal patch? Re-evaluate as a delta."
- "Elaborate on the top risk with a detailed mitigation plan and timeline."
- "Draft the Target Product Profile based on this design."
- "Estimate the IND-enabling study package: scope, timeline, budget range."
Frequently asked questions
Does the Drug Design Lab replace a medicinal chemistry team?
No. It generates design hypotheses, scaffold rationale, risk tables, and first-experiment plans that a medicinal chemist or formulation scientist can evaluate. It does not run assays or replace bench validation.
What about Predict and Optimize features?
Predict & Optimize routines are gated behind real uploaded bench data. Without your DoE, PK, stability, or assay outputs, no prediction is produced.
What outputs does it produce?
Disease intelligence, client-context snapshot, three interrogation questions, and a 7-section design report (Hypothesis, Scaffold, Data Signals, Known Failures Avoided, Top 3 Risks, First Experiment, Confidence Assessment).
Is there a follow-up conversation mode?
Yes. After Stage E renders, a follow-up panel opens with the full report in context. Typical follow-ups: scaffold variants, route switches, TPP drafting, IND-enabling scope estimation.